Independent Association of Circulating Vitamin D Metabolites with Anemia Risk in Patients Scheduled for Cardiac Surgery

Jana B. Ernst1*, Tobias Becker1‡, Joachim Kuhn2‡, Jan F. Gummert1‡, Armin Zittermann1☯

1 Clinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany, 2 Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany

* These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* azittermann@hdz-nrw.de

Abstract

Background
Preoperative anemia is considered an independent risk factor of poor clinical outcome in cardiac surgical patients. Low vitamin D status may increase anemia risk.

Methods
We investigated 3,615 consecutive patients scheduled for cardiac surgery to determine the association between preoperative anemia (hemoglobin [Hb] <12.5 g/dL) and circulating levels of the vitamin D metabolites 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25(OH)2D).

Results
Of the study cohort, 27.8 % met the criteria for anemia. In patients with deficient 25OHD levels (<30 nmol/l) mean Hb concentrations were 0.5 g/dL lower than in patients with adequate 25OHD levels (50.0–125 nmol/l; P<0.001). Regarding 1,25(OH)2D, mean Hb concentrations were 1.2 g/dL lower in the lowest 1,25(OH)2D category (<40 pmol/l) than in the highest 1,25(OH)2D category (>70 pmol/l; P<0.001). In multivariable–adjusted logistic regression analyses, the odds ratios for anemia of the lowest categories of 25OHD and 1,25(OH)2D were 1.48 (95%CI:1.19-1.83) and 2.35 (95%CI:1.86-2.97), compared with patients who had adequate 25OHD levels and 1,25(OH)2D values in the highest category, respectively. Anemia risk was greatest in patients with dual deficiency of 25OHD and 1,25(OH)2D (multivariable-adjusted OR = 3.60 (95%CI:2.40-5.40). Prevalence of deficient 25OHD levels was highest in anemia of nutrient deficiency, whereas low 1,25(OH)2D levels were most frequent in anemia of chronic kidney disease.
Conclusion
This cross-sectional study demonstrates an independent inverse association between vitamin D status and anemia risk. If confirmed in clinical trials, preoperative administration of vitamin D or activated vitamin D (in case of chronic kidney disease) would be a promising strategy to prevent anemia in patients scheduled for cardiac surgery.

Introduction
Anemia is a worldwide public health problem. With an estimated prevalence of 24.8%, it affects nearly one out of four of the global population [1]. The prevalence of anemia in patients undergoing cardiac surgery varies between 22.0% and 54.4% [2-5].

There is evidence from several observational studies that preoperative anemia is an independent predictor of poor clinical outcome in cardiac [2-4, 6-8] and non-cardiac [9] surgical patients. Different peri- and postoperative complications such as infections [3, 6, 7], stroke [2, 7] and renal failure [2, 7, 10], as well as prolonged ventilatory support [3, 7] and intensive care unit and in-hospital stay [3, 8, 9], were significantly associated with preoperative anemia. In addition, preoperative anemia is an independent risk factor of in-hospital and all-cause mortality [2, 6, 7, 9].

It has recently been shown that 25-hydroxyvitamin D (25OHD) deficiency is independently associated with lower hemoglobin (Hb) levels and higher anemia risk in patients scheduled for cardiac surgery [5]. The association between vitamin D deficiency and anemia is supported by various observational studies in different groups of patients [11-14]. Data in end-stage heart failure patients also indicate that circulating levels of the active vitamin D hormone, 1,25-dihydroxyvitamin D (1,25(OH)2D), is a better predictor of anemia than circulating 25OHD [14]. In line with these findings, first interventional studies in hemodialysis patients demonstrated an increase in Hb levels after intravenous administration of 1,25(OH)2D3, resulting in improved control of anemia [15, 16]. Experimental studies have provided evidence for potential mechanisms regarding how vitamin D may contribute to anemia prevention [17, 18]. Briefly, 1,25(OH)2D may influence bone marrow by stimulating erythropoiesis in red cell precursor cells via increased erythropoietin (EPO) sensitivity. Moreover, 1,25(OH)2D has the capacity to upregulate proliferation of progenitor cells, independent of the presence of EPO.

The present study therefore aimed to investigate the association of preoperative 25OHD and 1,25(OH)2D levels with the risk of anemia in patients scheduled for cardiac surgery.

Subjects and Methods
Patients
For this cross-sectional study, we considered 3,852 adult patients who were scheduled for cardiac surgery at our institution between February 2012 and December 2013 (geographic latitude 52°N). We excluded 237 patients with incomplete data sets, e.g. missing 25OHD levels, 1,25(OH)2D levels and/or Hb levels, leaving a total of 3,615 patients for data analysis. The vast majority of patients were Caucasians. This investigation is a secondary analysis of the CALCI-TOP-study which was approved by the Ethics Committee Ruhr University Bochum at Bad Oeynhausen, was registered at clinicaltrials.gov as NCT02192528, and was recently published [19]. Participants provided their written confirmed consent. All patient information was anonymized and de-identified prior to analysis.
Study Design

For analysis, we used routinely collected and filed demographic and clinical patient data (THGQIMS, Münster, Germany) and biochemical patient data (Lauris, SWISSLAB, Berlin, Germany). Blood samples were collected and analyzed on the last day before cardiac surgery. We assessed levels of 25OHD, 1,25(OH)₂D and Hb, as well as other biochemical parameters (creatinine, C-reactive protein [CRP], leukocytes, erythrocytes, hematocrit [Htc], mean corpuscular volume [MCV], mean corpuscular hemoglobin [MCH], thrombocytes, red blood cell distribution width). In addition, we assessed patient characteristics like age, gender, season of blood sampling, body mass index, smoking, left ventricular ejection fraction [LVEF], concomitant diseases (myocardial infarction [MI], chronic obstructive pulmonary disease [COPD], stroke, hemofiltration, peripheral arterial occlusive disease [PAOD], hypertension, diabetes, hyperlipidemia) and medication use (diuretics, angiotensin-converting enzyme-inhibitors, angiotensin receptor-blockers, aspirin, clopidogrel, glucocorticoids).

Biochemical Analysis

Circulating 1,25(OH)₂D₃ levels were measured by a liquid chromatography/tandem mass spectrometry method provided by Immundiagnostik (Bensheim, Germany). Since the detection limit of the method is 14 pmol/l, we considered values below this limit as 13.0 pmol/l. Circulating 25OHD levels (sum of 25[OH]D₂ and 25[OH]D₃) were analyzed by the autoanalyzer Liaison (DiaSorin, Stillwater, MN, USA). The measuring range was between 10 and 375 nmol/l. Values below the detection limit of 10.0 nmol/l were considered 9.9 nmol/l. CRP and creatinine levels were measured using the Architect Autoanalyzer (Abbott, Wiesbaden, Germany). Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease [20]. Blood Hb, Htc, erythrocytes, thrombocytes, MCV and MCH were measured by automated procedures using the Abbott CellDyn 3500 hematology analyzer (Abbott, Wiesbaden, Germany). According to earlier classifications [2, 5], Hb concentrations <12.5 g/dL were considered as anemic, which is the average threshold value of the World Health Organization’s gender-based definition (<13 g/dL in men and <12.0 g/dL in women). The following reference values were used for other hematological parameters: erythrocytes: males: 4.5–6.9 10¹²/l, females: 4.0–5.2 10¹²/l; Htc: males: 41–53%, females: 36–46%; MCH: 26–34 pg Hb/erythrocytes; MCV: 80–94 μm³. Together with low Hb levels, low MCV values can be an indicator of iron deficiency, whereas high MCV values can be an indicator of folate and/or vitamin B₁₂ deficiency [21]. Therefore, we used earlier approaches to classify anemia hierarchically according to subtypes [5, 22]: anemia because of nutritional deficiency (iron deficiency: MCV <80 μm³, folate or vitamin B₁₂ deficiency: MCV: >94 μm³), anemia of chronic kidney disease (CKD; eGFR: <60 ml/min per 1.73 m²), anemia of inflammation (CRP >10 mg/l) and unexplained anemia if none of these subtypes were present.

Statistics

Categorical variables are reported as a percentage of observations. Continuous variables are presented as a mean and standard deviation. Clinical and demographic parameters of anemic and non-anemic patients were compared using Student’s t test, Chi-squared test and ANOVA. All continuous variables were normally distributed (Kolmogorov-Smirnov test). According to the Institute of Medicine [23], the following 25OHD cutoff values were used for classifying vitamin D status: deficiency (<30 nmol/l), inadequacy (30–49.9 nmol/l), adequacy (50–125 nmol/l) and potentially harmful (>125 nmol/l). Based on earlier classifications [14, 24], 1,25(OH)₂D values were divided into three categories (<40 pmol/l; 40–70 pmol/l; >70 pmol/l).
To assess the independent association of 25OHD and 1,25(OH)₂D categories with anemia, we performed logistic regression analysis (unadjusted and multivariable-adjusted). Results are expressed as odds ratios (ORs) with a 95% confidence interval. We considered the groups with adequate 25OHD levels (50–125 nmol/l) and 1,25(OH)₂D levels >70 pmol/l as a reference group. The following covariates were included in multivariable models: model 1: unadjusted data; model 2: adjusted for age, gender and season of blood sampling (winter: January through March; spring: April through June; summer: July through September; fall: October through December); model 3: model 2 plus adjustments for body mass index, smoking, LVEF, concomitant diagnoses (MI, COPD, stroke, hemofiltration, PAOD, hypertension, diabetes and hyperlipidemia) and medications (diuretics, angiotensin-converting enzyme-inhibitors, angiotensin receptor-blockers, aspirin, clopidogrel, glucocorticoids); model 4: model 3 plus adjustments for kidney function (eGFR in ml/min per 1.73 m²) and inflammatory processes (CRP in mg/dL). In sensitivity analysis, we also used the following 25OHD classification: <50 nmol/l, 50–125 nmol/l and >125 nmol/l. We considered the P-values <0.05 as statistically significant. P-values are two-sided. Analyses were performed using SPSS version 21.0 (SPSS, Inc., Chicago, IL, USA).

Results

Of the study cohort, 26.1% were 25OHD deficient (<30.0 nmol/l), 35.4% had inadequate 25OHD values (30–49.9 nmol/l), 36.7% had adequate 25OHD values (50–125 nmol/l) and 1.7% had values >125 nmol/l. Regarding 1,25(OH)₂D, 29.4% had values below 40 pmol/l, 40.6% values between 40 and 70 pmol/l and 30.0% had values >70 pmol/l. Baseline characteristics of the study cohort are listed in Table 1, broken down by anemia status. Of the study cohort, 27.8% met the criteria for anemia. Compared with non-anemic patients, circulating 25OHD and 1,25(OH)₂D levels were significantly lower in anemic patients. Anemic patients were significantly older, more frequently female but less often smokers than non-anemic patients. In addition, anemic patients had significantly lower LVEF values and suffered more often from COPD, hemofiltration, PAOD, diabetes and hyperlipidemia than non-anemic patients. In addition, anemia was associated with reduced Hb, Htc, MCV, MCH and erythrocyte values, but MCV, MCH and erythrocyte values were still within the respective reference range. CRP was significantly elevated in the anemic group.

Tables 2 and 3 illustrate the hematological parameters broken down by 25OHD status and 1,25(OH)₂D categories, respectively. Anemia risk was greatest in the groups with the lowest 25OHD and 1,25(OH)₂D concentrations. In detail, mean Hb concentrations were 0.5 g/dL lower in patients with deficient levels of 25OHD levels (<30 nmol/l) than in patients with adequate 25OHD levels (50–125 nmol/l; P<0.001). Regarding 1,25(OH)₂D, mean Hb concentrations were 1.2 g/dL lower in patients in the lowest 1,25(OH)₂D category (<40 pmol/l) than in the highest 1,25(OH)₂D category (>70 pmol/l; P<0.001). Hematological parameters, such as erythrocytes, Htc, MCH and MCV, were all lowest in patients with low 1,25(OH)₂D levels. MCV and MCH were lowest in patients with deficient 25OHD levels, whereas erythrocytes and Htc were lowest in patients with 25OHD levels >125 nmol/l. MCV differed significantly between 25OHD categories, but not between 1,25(OH)₂D categories.

In Tables 4 and 5, the ORs for anemia are given by categories of 25OHD and 1,25(OH)₂D. In the unadjusted model, the ORs for patients in the lowest categories of 25OHD and 1,25(OH)₂D were significantly higher = 1.79 (95% CI: 1.49–2.15) and 3.73 (95% CI: 3.05–4.56), compared with the respective reference group. In the fully adjusted models, the ORs for anemia were attenuated, but remained significant. Compared with the respective reference group, the OR for the category of 25OHD deficient patients was = 1.48 (95% CI: 1.19–1.83) and was = 2.35 (95% CI: 1.86–2.97) for the lowest 1,25(OH)₂D category.
In patients with dual deficiency of 25OHD and 1,25(OH)₂D (n = 336), the fully adjusted OR for anemia was compared with patients who had adequate 25OHD levels and 1,25(OH)₂D levels in the highest category (n = 438) = 3.60 (95% CI: 2.40–5.40; P < 0.001). In sensitivity analysis, the fully adjusted OR of patients with 25OHD values < 50 nmol/l was = 1.21 (95% CI: 1.01–1.45), compared with the reference group of 50–125 nmol/l.

Table 1. Characteristics of the study cohort by anemia status.

|                      | Anemic (<12.5 g/dl) n = 1,006 | Non-anemic (≥12.5 g/dl) n = 2,609 | P value |
|----------------------|-------------------------------|-----------------------------------|---------|
| **Age (years)**      | 72±10.7                       | 67±11.1                           | <0.001  |
| Gender (% males)     | 47.5                          | 74.7                              | <0.001  |
| BMI (kg/m²)          | 27.5±5.3                      | 27.8±4.3                          | 0.114   |
| Smokers (%)          | 21.2                          | 31.8                              | <0.001  |
| LVEF (%)             | 56.3±12.5                     | 57.8±12.1                         | 0.001   |
| **Concomitant diseases** |                              |                                   |         |
| MI (%)               | 19.2                          | 16.8                              | 0.096   |
| COPD (%)             | 11.2                          | 7.8                               | 0.001   |
| Stroke (%)           | 6.3                           | 4.6                               | 0.051   |
| Hemofiltration (%)   | 5.3                           | 0.4                               | <0.001  |
| PAOD (%)             | 9.7                           | 6.6                               | 0.002   |
| Hypertension (%)     | 80.9                          | 78.8                              | 0.183   |
| Diabetes (%)         | 34.6                          | 22.9                              | <0.001  |
| Hyperlipidemia (%)   | 62.6                          | 66.4                              | 0.035   |
| **Medications**      |                               |                                   |         |
| Diuretics (%)        | 57.8                          | 36.7                              | <0.001  |
| ACE-Inhibitors (%)   | 47.6                          | 45.2                              | 0.192   |
| AT-blockers (%)      | 12.9                          | 11.4                              | 0.206   |
| Aspirin (%)          | 50.7                          | 44.9                              | 0.002   |
| Clopidogrel (%)      | 9.2                           | 6.7                               | 0.013   |
| Glucocorticoids (%)  | 4.0                           | 2.9                               | 0.114   |
| **Biochemical parameters** |                          |                                   |         |
| eGFR (ml/min/1.73 m²) | 64.1±26.2                     | 78.6±20.6                         | <0.001  |
| CRP (mg/dl)          | 2.3±4.7                       | 0.7±1.6                           | <0.001  |
| 25OHD (nmol/l)       | 46.9±30.4                     | 49.3±26.0                         | 0.026   |
| 1,25(OH)₂D (pmol/l)  | 46.7±26.8                     | 60.6±27.5                         | <0.001  |
| Hemoglobin (g/dl)    | 11.1±1.1                      | 14.3±1.1                          | <0.001  |
| Leukocytes (10⁹/l)   | 8.2±3.8                       | 7.8±3.1                           | 0.003   |
| Erythrocytes (10¹²/l) | 3.8±0.5                       | 4.6±0.4                           | <0.001  |
| Hematocrit (%)       | 33.5±3.2                      | 41.9±3.3                          | <0.001  |
| MCV (μm³)            | 89.3±6.3                      | 90.4±4.5                          | <0.001  |
| MCH (pg Hb/red blood cell) | 29.6±2.6                     | 30.8±1.8                          | <0.001  |
| Thrombocytes (10⁹/l) | 249±100.8                     | 231±72.7                          | <0.001  |
| RDW (%)              | 14.0±2.2                      | 12.4±1.2                          | <0.001  |

ACE = Angiotensin-converting-enzyme; AT = Angiotensin receptor; BMI = Body Mass Index; COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; eGFR = estimated globular filtration rate; Hb = Hemoglobin; LVEF = Left ventricular ejection fraction; MCH = mean corpuscular/cellular hemoglobin; MCV = mean corpuscular/cell volume; MI = myocardial infarction; PAOD = peripheral artery occlusive disease; RDW = Red Blood Cell Distribution Width ([Sv x 100]/MCV)

doi:10.1371/journal.pone.0124751.t001
### Table 2. Hematological parameters by cutoffs of 25-Hydroxyvitamin D.

| 25OHD nmol/l | <30 n = 945 | 30–49.9 n = 1281 | 50–125 n = 1328 | >125 n = 61 | P value for trend |
|--------------|-------------|-----------------|-----------------|----------|------------------|
| Hemoglobin (g/dl) | 13.0±2.0 | 13.5±1.8 | 13.5±1.7 | 12.8±1.8 | <0.001 |
| Erythrocytes (10¹²/l) | 4.3±0.6 | 4.4±0.6 | 4.4±0.6 | 4.2±0.5 | <0.001 |
| Hematocrit (%) | 38.7±5.4 | 39.8±5.0 | 39.9±4.6 | 38.2±4.8 | <0.001 |
| MCV (μm³) | 89.7±5.9 | 90.2±4.9 | 90.3±4.5 | 90.8±5.9 | 0.034 |
| MCH (pg Hb/Erythrocytes) | 30.2±2.5 | 30.6±2.0 | 30.6±1.8 | 30.4±2.5 | <0.001 |

Hb = Hemoglobin; MCH = mean corpuscular/cellular hemoglobin; MCV = mean corpuscular/cell volume.

doi:10.1371/journal.pone.0124751.t002

### Table 3. Hematological parameters by cutoffs of 1,25-Dihydroxyvitamin D.

| 1,25(OH)₂D pmol/l | <40 n = 1064 | 40–70 n = 1468 | >70 n = 1083 | P value for trend |
|-------------------|-------------|----------------|--------------|------------------|
| Hemoglobin (g/dl) | 12.7±1.9 | 13.5±1.7 | 13.9±1.6 | <0.001 |
| Erythrocytes (10¹²/l) | 4.2±0.6 | 4.4±0.6 | 4.6±0.5 | <0.001 |
| Hematocrit (%) | 37.6±5.3 | 39.9±4.8 | 40.8±4.3 | <0.001 |
| MCV (μm³) | 89.9±5.6 | 90.3±4.9 | 90.0±4.8 | 0.101 |
| MCH (pg Hb/Erythrocytes) | 30.2±2.3 | 30.6±2.0 | 30.6±2.0 | <0.001 |

Hb = Hemoglobin; MCH = mean corpuscular/cellular hemoglobin; MCV = mean corpuscular/cell volume.

doi:10.1371/journal.pone.0124751.t003

### Table 4. Unadjusted and adjusted odds ratio (OR) for anemia by cutoffs of 25-Hydroxyvitamin D.

| 25OHD nmol/l | N | Anemia (%) | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) | Model 4 OR (95% CI) |
|--------------|---|------------|---------------------|---------------------|---------------------|---------------------|
| <30 | 945 | 337 (35.7) | 1.79 (1.49–2.15) | 1.63 (1.34–1.98) | 1.50 (1.22–1.84) | 1.48 (1.19–1.83) |
| 30–49.9 | 1281 | 331 (25.8) | 1.13 (0.94–1.34) | 1.06 (0.88–1.28) | 1.06 (0.87–1.28) | 1.05 (0.85–1.28) |
| 50–125 | 1328 | 314 (23.6) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) |
| >125 | 61 | 24 (39.3) | 2.10 (1.23–3.56) | 2.27 (1.30–3.96) | 1.69 (0.92–3.10) | 1.34 (0.71–2.52) |

Model 1: unadjusted
Model 2: adjusted for age, gender and season of blood drawing
Model 3: adjusted as in model 2 and for concomitant diseases, medications, smoking, body mass index and left ventricular ejection fraction
Model 4: adjusted as in model 3 and for kidney function (eGFR) and inflammatory process (CRP)

doi:10.1371/journal.pone.0124751.t004

### Table 5. Unadjusted and adjusted odds ratio (OR) for anemia by cutoffs of 1,25-Dihydroxyvitamin D.

| 1,25(OH)₂D pmol/l | N | Anemia (%) | Model 1 OR (95% CI) | Model 2 OR (95% CI) | Model 3 OR (95% CI) | Model 4 OR (95% CI) |
|-------------------|---|------------|---------------------|---------------------|---------------------|---------------------|
| <40 | 1064 | 452 (42.5) | 3.73 (3.05–4.56) | 3.50 (2.83–4.33) | 2.97 (2.38–3.71) | 2.35 (1.86–2.97) |
| 40–70 | 1468 | 375 (25.5) | 1.73 (1.42–2.11) | 1.69 (1.37–2.08) | 1.60 (1.29–1.98) | 1.52 (1.22–1.89) |
| >70 | 1083 | 179 (16.5) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) |

Model 1: unadjusted
Model 2: adjusted for age, gender and season of blood drawing
Model 3: adjusted as in model 2 and for concomitant diseases, medications, smoking, body mass index and left ventricular ejection fraction
Model 4: adjusted as in model 3 and for kidney function (eGFR) and inflammation (CRP)

doi:10.1371/journal.pone.0124751.t005
The prevalence of deficient 25OHD levels was highest in anemia of nutrient deficiency, whereas low 1,25(OH)2D levels were most frequent in anemia of CKD (Figs 1 and 2).

### Discussion

This cross-sectional study demonstrates that low 25OHD and 1,25(OH)2D levels are independently associated with low Hb levels and anemia risk in patients scheduled for cardiac surgery. Patients with 25OHD values <30 nmol/l and 1,25(OH)2D values <40 pmol/l had the highest risk for anemia, whereas the risk was lowest in patients with adequate 25OHD levels (50–125 nmol/l) and 1,25(OH)2D levels above 70 pmol/l. Circulating 1,25(OH)2D was a better predictor of anemia than circulating 25OHD.

Our data confirm earlier studies of an independent inverse association between circulating 25OHD and anemia risk [5, 11, 12, 22, 25–30]. However, the association of 1,25(OH)2D with anemia risk has rarely been studied, and the few available studies on this topic have primarily been performed in patients with CKD and end-stage heart failure [13] [14]. In end-stage heart failure [14], Hb concentrations were 1.6 g/dL higher in patients with values >70 pmol/l.
compared to patients with values < 40 pmol/l. These earlier findings are in general agreement with the data of the present study.

There are several suggested causes why low 1,25(OH)2D may play a role in the development of anemia. Vitamin D modulates the level of systemic cytokine production. Therefore, vitamin D may reduce the inflammatory milieu that leads to anemia of chronic disease [11]. In addition, vitamin D may influence folate and iron absorption by increasing intestinal proton-coupled folate transporter [31] [32]. Iron participates in the renal activation of 25OHD into 1,25(OH)2D [33]; the enzymatic conversion is catalyzed by a cytochrome P450-dependent ferrodoxin reductase [34]. 1,25(OH)2D can also stimulate erythropoiesis in red blood cell precursor cells by increasing EPO sensitivity and can up-regulate proliferation of progenitor cells [17, 18]. First interventional studies support the hypothesis that 1,25(OH)2D administration and probably also high-dose bolus application of vitamin D is effective in enhancing Hb levels. Briefly, two studies in patients with CKD demonstrated an increase in mean Hb concentration after 12 months of intravenous 1,25(OH)2D administration by 1.0 mg/dL [15] and 1.2 mg/dL [16], and therefore improved control of anemia with reduced need for EPO. However, results must be considered preliminary since no control group was included in the two studies. In another

Fig 2. Prevalence of 1,25(OH)2D levels <40 pmol/l according to subtypes of anemia. There were significant differences between subgroups (P<0.001). Number of patients in brackets.

doi:10.1371/journal.pone.0124751.g002
study in hemodialysis patients, intravenous administration of 1,25(OH)₂D decreased the weekly EPO dose requirement by 50% [35]. Similarly, high-dose monthly oral vitamin D₂ administration (50,000 IU) was associated with non-significant [36] and significant [37] reductions in doses of erythropoiesis-stimulating agents (ESA), while mean Hb levels remained unchanged. Interestingly enough, it has been demonstrated that high-dose oral bolus administration of vitamin D is even able to increase circulating 1,25(OH)₂D levels in CKD patients [38].

Data obtained in the United States demonstrate that blood transfusion is the most common procedure performed during hospitalization (11.0% of hospital stays with a procedure) [39]. With a range of 35.8% to 60.0%, the transfusion rate in patients undergoing a cardiovascular procedure is very high [40–46]. However, the use of blood transfusion involves several risks. Blood transfusion is an independent risk factor for clinical complications like prolonged ventilatory support [3, 7], increased length of hospital stay [45, 46], infection [43–45, 47] and mortality [40–43, 45]. The increased risk of blood transfusion has been attributed to the presence of leucocytes in allogeneic blood transfusion thereby causing immunomodulatory events [48]. In addition, duration of blood storage influences clinical outcome with higher incidence of prolonged mechanical ventilation, renal failure, sepsis and in-hospital mortality in patients receiving older blood products (>14 days) [49]. Besides the use of leukocyte-depleted red blood cells and short storage time, reduction or even avoidance of the use of blood transfusion might be another interesting approach. Anemia is the most important risk factor for transfusion [50]. If confirmed in randomized controlled trials, administration of vitamin D or its active form 1,25(OH)₂D could be a promising preventive or therapeutic option to decrease the prevalence of anemia in elective cardiac surgical patients. Of note, CKD patients (stages IV and V) should preferably be treated with activated vitamin D.

In our study, prevalence of deficient 25OHD levels was highest in anemia of nutrient deficiency, whereas low 1,25(OH)₂D levels were most frequent in anemia of chronic kidney disease. With regard to CKD, this may be due to low GFR, resulting in reduced 1,25(OH)₂D synthesis. However, it may also be that CKD-induced increased 24-hydroxylase activity [51] leads to enhanced conversion of 25OHD and 1,25(OH)₂D into their 24-hydroxylated inactive forms. It is well known that 1,25(OH)₂D levels are suppressed in CKD. However, low 1,25(OH)₂D levels were also present in anemia of inflammation and anemia of nutrient deficiency. It has recently been shown that low 1,25(OH)₂D levels are independently associated not only with poor kidney function but also with low 25OHD levels, high CRP levels, diabetes mellitus and high values of the cardio-surgical risk marker EuroSCORE [19]. It may therefore well be that the anemia subtype 'nutrient deficiency' may only be a surrogate for poor health status and that circulating 1,25(OH)₂D levels are also suppressed by other, currently unknown factors.

Our study has some strengths but also some limitations. Its strengths are measurement of the active vitamin D hormone, 1,25(OH)₂D, in a large cohort of patients and adjustments for several demographical and clinical variables. One inherent limitation is the observational study design, which prevents us from concluding that the association between 25OHD and 1,25(OH)₂D deficiency and anemia is causal. It is another limitation that we were unable to assess the use of ESA or to measure EPO concentrations. However, since the association of low 1,25(OH)₂D levels with anemia was highest in anemia of CKD, it is rather unlikely that ESA were frequently used in our study cohort. Finally, no data on parathyroid hormone, magnesium or fibroblast growth factor 23 levels were available, parameters that are involved in 1,25(OH)₂D regulation and therefore play a central role in vitamin D metabolism.

In conclusion, our study demonstrates that 25OHD and 1,25(OH)₂D levels are independently associated with low Hb concentrations and high anemia risk in cardiac surgical patients. Circulating 1,25(OH)₂D was a better predictor of anemia than circulating 25OHD. Future studies have to clarify whether the association is causal and whether preoperative
administration of vitamin D or 1,25(OH)2D is able to successfully prevent or treat anemia in patients scheduled for cardiac surgery.

Author Contributions
Conceived and designed the experiments: AZ. Performed the experiments: JBE JK. Analyzed the data: JBE TB AZ. Contributed reagents/materials/analysis tools: JK JFG. Wrote the paper: JBE AZ.

References
1. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr. 2009; 12: 444–54. doi: 10.1017/S1368946508003917 PMID: 19498676
2. Karkouti K, Wijeysundera DN, Beattie WS. Risk associated with preoperative anemia in cardiac surgery: a multicenter cohort study. Circulation. 2008; 117: 478–84. doi: 10.1161/CIRCULATIONAHA.107.718553 PMID: 18172032
3. Kim C, Connell H, McGeorge A, Hu R. Prevalence of preoperative anaemia in patients having first-time cardiac surgery and its impact on clinical outcome. A retrospective observational study. Perfusion. 2014. In press.
4. Carrascal Y, Maroto L, Rey J, Arevalo A, Arroyo J, Echevarria JR, et al. Impact of preoperative anemia on cardiac surgery in octogenarians. Interact Cardiovasc Thorac Surg. 2010; 10: 249–55. doi: 10.1510/icvts.2009.220160 PMID: 19869715
5. Zittermann A, Kuhn J, Dreier J, Knabbe C, Prokop S, Gummert JF, et al. Association of 25-hydroxyvitamin D with anemia risk in patients scheduled for cardiac surgery. Int J Lab Hematol. 2013. In press.
6. Shavit L, Hitti S, Silberman S, Tauber R, Merin O, Lifschitz M, et al. Preoperative Hemoglobin and Outcomes in Patients with CKD Undergoing Cardiac Surgery. Clin J Am Soc Nephrol. 2014; 9: 1536–44. doi: 10.2215/CJN.00110114 PMID: 24993450
7. Williams ML, He X, Rankin JS, Slaughter MS, Gammie JS. Preoperative hematocrit is a powerful predictor of adverse outcomes in coronary artery bypass graft surgery: a report from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg. 2013; 96: 1628–34. doi: 10.1016/j.athoracsur.2013.06.030 PMID: 24055236
8. Hung M, Besser M, Sharples LD, Nair SK, Klein AA. The prevalence and association with transfusion, intensive care unit stay and mortality of pre-operative anaemia in a cohort of cardiac surgery patients. Anaesthesia. 2011; 66: 812–8. doi: 10.1111/j.1365-2044.2011.06819.x PMID: 21790620
9. Baron DM, Hochrieter H, Posch M, Mehlitz B, Rhodes A, Moreno RP, et al. Preoperative anemia is associated with poor clinical outcome in non-cardiac surgery patients. Br J Anaesth. 2014; 113: 416–23. doi: 10.1093/bja/aeu098 PMID: 24829444
10. Harskamp RE, Alexander JH, Schulte PJ, Jones WS, Williams JB, Mack MJ, et al. Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery. Ann Thorac Surg. 2014; 97: 824–30. doi: 10.1016/j.athoracsur.2013.09.099 PMID: 24360877
11. Sim JJ, Lac PT, Liu IL, Meguerditchian SO, Kumar VA, Kujubu DA, et al. Vitamin D deficiency and anemia: a cross-sectional study. Ann Hematol. 2010; 89: 447–52. doi: 10.1007/s00277-009-0650-9 PMID: 19841921
12. Lac PT, Choi K, Liu IA, Meguerditchian S, Rason S, Sim JJ. The effects of changing vitamin D levels on anemia in chronic kidney disease patients: a retrospective cohort review. Cln Nephrol. 2010; 74: 25–32. PMID: 20557865
13. Patel NM, Gutierrez OM, Andress DL, Coyne DW, Levin A, Wolf M. Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int. 2010; 77:715–20. doi: 10.1038/ki.2009.551 PMID: 2030525
14. Zittermann A, Jungvogel A, Prokop S, Kuhn J, Dreier J, Fuchs U, et al. Vitamin D deficiency is an independent predictor of anemia in end-stage heart failure. Clin Res Cardiol. 2011; 100: 781–8. doi: 10.1007/s00392-011-0312-5 PMID: 21472493
15. Goicoechea M, Vazquez MI, Ruiz MA, Gomez-Campderas F, Perez-Garcia R, Vallederrabano F. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron. 1998; 78: 23–7. PMID: 9453399
16. Neves PL, Trivino J, Casaubon F, Santos V, Mendes P, Romao P, et al. Elderly patients on chronic haemodialysis with hyperparathyroidism: increase of hemoglobin level after intravenous calcitriol. Int Urol Nephrol. 2006; 38: 175–7. PMID: 16502078
17. Aucella F, Scalzulli RP, Gatta G, Vigilante M, Carella AM, Stallone C. Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo. Nephron Clin Pract. 2003; 95: c121–7. PMID: 14694273

18. Alon DB, Chaimovitz C, Dviliansky A, Lugassy G, Doudevani A, Shany S, et al. Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp Hematol. 2002; 30: 403–9. PMID: 12031646

19. Zittermann A, Kuhn J, Ernst JB, Becker T, Dreier J, Knabbe C, et al. 25-hydroxyvitamin d, 1,25-dihy- droxyvitamin d and postoperative outcome in cardiac surgery. J Clin Endocrinol Metab. 2015; 100: 72–80. doi: 10.1210/jc.2014-3013 PMID: 25365313

20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glo- merular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130: 461–70. PMID: 10075613

21. Neumeister B, Besenthal I, Boehm BO. Klinikleitfaden Labordiagnostik. 4th ed. Munich, Jena: Else- vier; 2009.

22. Perlstein TS, Pande R, Berliner N, Vanasse GJ. Prevalence of 25-hydroxyvitamin D deficiency in sub- groups of elderly persons with anemia: association with anemia of inflammation. Blood. 2011; 117: 2800–6. doi: 10.1182/blood-2010-09-309708 PMID: 21239700

23. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011; 96: 53–8. doi:10.1210/jc.2010-2704 PMID: 21118827

24. Zittermann A, Schleithoff SS, Frisch S, Gotting C, Kuhn J, Koertke H, et al. Circulating calcitriol concen- trations and total mortality. Clin Chem. 2009; 55: 1163–70. doi: 10.1373/clinchem.2008.120006 PMID: 19359534

25. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. Am J Nephrol. 2009; 30: 64–72. PMID:10.1159/000202632 PMID: 19218791

26. Kiss Z, Ambrus C, Almasi C, Berta K, Deak G, Horonyi P, et al. Serum 25(OH)-cholecalciferol concen- tration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance he- modialysis. Nephron Clin Pract. 2011; 117: c373–8. doi: 10.1159/000321521 PMID: 21071961

27. Atkinson MA, Melamed ML, Kumar J, Roy CN, Miller ER 3rd, Furth SL, et al. Vitamin D, race, and risk for anemia in children. J Pediatr. 2014; 164: 153–8 e1. doi: 10.1016/j.jpeds.2013.08.060 PMID: 24112861

28. Lawson M, Thomas M. Vitamin D concentrations in Asian children aged 2 years living in England: popu- lation survey. BMJ. 1999; 318: 28. PMID: 9872879

29. Mehta S, Giovannucci E, Mugusi FM, Spiegelman D, Aboud S, Hertzmark E, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PloS One. 2010; 5: e8770. doi: 10.1371/journal.pone.0008770 PMID: 20098738

30. Shin JY, Shim JY. Low vitamin D levels increase anemia risk in Korean women. Clin Chim Acta. 2013; 421: 177–80. doi: 10.1016/j.cca.2013.02.025 PMID: 23466002

31. Eloranta JJ, Zair ZM, Hiller C, Hausler S, Stieger B, Kullak-Ublick GA. Vitamin D3 and its nuclear recep- tore increase the expression and activity of the human proton-coupled folate transporter. Mol Pharmacol. 2009; 76: 1062–71. doi: 10.1124/mol.109.055392 PMID: 19666701

32. Masuhara T, Migicovsky BB. Vitamin D and the intestinal absorption of iron and cobalt. J Nutr. 1963; 80: 332–6. PMID: 13933502

33. Blanco-Rojo R, Perez-Granados AM, Toxqui L, Zazo P, de la Piedra C, Vaquero MP. Relationship be- tween vitamin D deficiency, bone remodelling and iron status in iron-deficient young women consuming an iron-fortified food. Eur J Nutr. 2013; 52: 695–703. doi: 10.1007/s00394-012-0375-8 PMID: 22618893

34. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Phys- iol Rev. 1998; 78: 1193–231. PMID: 9790574

35. Nazem AK, Mako J. The effect of calcitriol on renal anaemia in patients undergoing long-term dialysis. Int Urol Nephrol. 1997; 29: 119–27. PMID: 9203048

36. Kumar VA, Kujubu DA, Sim JJ, Rasgon SA, Yang PS. Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients. J Nephrol. 2011; 24: 98–105. PMID: 20563998

37. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW. Prevalence of vitamin D deficien- cy and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract. 2007; 105: c132–8. PMID: 17228173
38. Jean G, Souberbielle JC, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant. 2009; 24: 3799–805. doi: 10.1093/ndt/gfp370 PMID: 19622574

39. Healthcare Cost and Utilization Project. Most Frequent Procedures Performed in U.S. Hospitals, 2010. 2013 [updated 21.10.2014]; Available from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb149.pdf.

40. Surgenor SD, Kramer RS, Olmstead EM, Ross CS, Sellke FW, Likosky DS, et al. The association of perioperative red blood cell transfusions and decreased long-term survival after cardiac surgery. Anesth Analg. 2009; 108: 1741–6. doi: 10.1213/ane.0b013e3181a2a696 PMID: 19448195

41. Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006; 34: 1608–16. PMID: 16607235

42. Engoren M, Schwann TA, Habib RH, Neil SN, Vance JL, Likosky DS. The independent effects of anemia and transfusion on mortality after coronary artery bypass. The Ann Thorac Surg. 2014; 97: 514–20. doi: 10.1016/j.jathoracsur.2013.09.019 PMID: 24206967

43. Paone G, Likosky DS, Brewer R, Theurer PF, Bell GF, Cogan CM, et al. Transfusion of 1 and 2 units of red blood cells is associated with increased morbidity and mortality. The Ann Thorac Surg. 2014; 97: 87–93. doi: 10.1016/j.jathoracsur.2013.07.020 PMID: 24094521

44. Whitson BA, Huddleston SJ, Savik K, Shumway SJ. Risk of adverse outcomes associated with blood transfusion after cardiac surgery depends on the amount of transfusion. J Surg Res. 2010; 158: 20–7. doi: 10.1016/j.jss.2008.10.015 PMID: 19181341

45. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. Circulation. 2007; 116: 2544–52. PMID: 17998460

46. Galas FR, Almeida JP, Fukushima JT, Osawa EA, Nakamura RE, Silva CM, et al. Blood transfusion in cardiac surgery is a risk factor for increased hospital length of stay in adult patients. J Cardiothorac Surg. 2013; 8: 54. doi: 10.1186/1749-8090-8-54 PMID: 23531208

47. Leal-Naval SR, Rincon-Ferrari MD, Garcia-Curiel A, Herruzo-Aviles A, Camacho-Larana P, Garnacho-Montero J, et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. Chest. 2001; 119: 1461–8. PMID: 11348954

48. Bilgin YM, van de Watering LM, Eijisman L, Versteegh M, Brand R, van Oers MH, et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation. 2004; 109: 2755–60. PMID: 15148271

49. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008; 358: 1229–39. doi: 10.1056/NEJMoa070403 PMID: 18354101

50. Spahn DR, Goodnough LT. Alternatives to blood transfusion. Lancet. 2013; 381: 1855–65. doi: 10.1016/S0140-6736(13)60808-9 PMID: 23706802

51. Petkovich M, Jones G. CYP24A1 and kidney disease. Curr Opin Nephrol Hypertens. 2011; 20: 337–44. doi: 10.1097/MNH.0b013e3283477a7b PMID: 21610497